Funds › Cormorant Asset Management, LP
Cormorant Asset Management, LP
13F for Q2 2026, filed Aug 14, 2026. 50 positions worth $2.0B.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q2 2026
filed Aug 14, 2026
Reported value
$2.0B
−$39.6M (2.0%) vs Q1 2026
Positions
50
46 in Q1 2026
Top 10 share
59.2%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Cormorant Asset Management, LP in the latest 13F quarter?
Using 13F.ai, how has Cormorant Asset Management, LP's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Cormorant Asset Management, LP's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | PRAX Praxis Precision Medicines, Inc. | 640,000 | $214.3M | 11.0% | -27.7% | 13F ↗ |
| 2 | BBOT BridgeBio Oncology Therapeutics, Inc. | 17.88M | $136.2M | 7.0% | Unchanged | 13F ↗ |
| 3 | PBLS Parabilis Medicines, Inc. | 4.62M | $126.3M | 6.5% | New | 13F ↗ |
| 4 | RAPP Rapport Therapeutics, Inc. | 2.66M | $110.7M | 5.7% | -10.1% | 13F ↗ |
| 5 | ERAS Erasca, Inc. | 6.00M | $109.9M | 5.6% | +3.4% | 13F ↗ |
| 6 | EWTX Edgewise Therapeutics, Inc. | 2.51M | $102.0M | 5.2% | -23.0% | 13F ↗ |
| 7 | EYPT EyePoint, Inc. | 7.00M | $100.1M | 5.1% | -15.3% | 13F ↗ |
| 8 | ALMS Alumis Inc. | 3.29M | $92.5M | 4.7% | -16.8% | 13F ↗ |
| 9 | ABVX Abivax SA · ADR | 675,000 | $90.0M | 4.6% | -11.2% | 13F ↗ |
| 10 | DNTH Dianthus Therapeutics, Inc. | 750,000 | $73.1M | 3.7% | -21.1% | 13F ↗ |
| 11 | DRUG Bright Minds Biosciences Inc. | 900,000 | $63.2M | 3.2% | -15.0% | 13F ↗ |
| 12 | MLTX MoonLake Immunotherapeutics | 3.21M | $62.4M | 3.2% | -28.5% | 13F ↗ |
| 13 | BIOA BioAge Labs, Inc. | 2.39M | $58.6M | 3.0% | -17.3% | 13F ↗ |
| 14 | ORKA Oruka Therapeutics, Inc. | 533,340 | $50.8M | 2.6% | Unchanged | 13F ↗ |
| 15 | ANL Adlai Nortye Group Ltd. · ADR | 3.98M | $45.7M | 2.3% | +37.3% | 13F ↗ |
| 16 | BBIO BridgeBio Pharma, Inc. | 550,000 | $41.0M | 2.1% | -35.3% | 13F ↗ |
| 17 | TNGX Tango Therapeutics, Inc. | 1.30M | $40.6M | 2.1% | -8.8% | 13F ↗ |
| 18 | BHVN Biohaven Ltd. | 2.61M | $38.8M | 2.0% | +48.3% | 13F ↗ |
| 19 | AGMB AgomAb Therapeutics NV · ADR | 2.47M | $32.0M | 1.6% | Unchanged | 13F ↗ |
| 20 | MBX MBX Biosciences, Inc. | 550,000 | $30.4M | 1.6% | -50.9% | 13F ↗ |
| 21 | CLYM Climb Bio, Inc. | 2.11M | $27.5M | 1.4% | New | 13F ↗ |
| 22 | OLMA Olema Oncology, Inc. | 2.15M | $26.9M | 1.4% | -44.9% | 13F ↗ |
| 23 | Damora Therapeutics Inc | 1.00M | $26.0M | 1.3% | -34.4% | 13F ↗ |
| 24 | PHVS Pharvaris N.V. | 750,000 | $25.9M | 1.3% | -25.0% | 13F ↗ |
| 25 | CRBP Corbus Pharmaceuticals Holdings, Inc. | 2.34M | $22.0M | 1.1% | Unchanged | 13F ↗ |
| 26 | SYRE Spyre Therapeutics, Inc. | 225,000 | $20.0M | 1.0% | New | 13F ↗ |
| 27 | DFTX Definium Therapeutics, Inc. | 400,000 | $18.8M | 1.0% | New | 13F ↗ |
| 28 | NAMS NewAmsterdam Pharma Company N.V. | 500,000 | $16.9M | 0.9% | -47.4% | 13F ↗ |
| 29 | ROIV Roivant Sciences Ltd. | 475,000 | $16.8M | 0.9% | -36.7% | 13F ↗ |
| 30 | CABA Cabaletta Bio, Inc. | 5.00M | $15.6M | 0.8% | -9.1% | 13F ↗ |
| 31 | HLXC Helix Acquisition Corp. III | 1.30M | $13.8M | 0.7% | Unchanged | 13F ↗ |
| 32 | ASND Ascendis Pharma A/S | 50,000 | $13.3M | 0.7% | New | 13F ↗ |
| 33 | KLRA Kailera Therapeutics, Inc. | 550,000 | $12.1M | 0.6% | New | 13F ↗ |
| 34 | INSM Insmed Incorporated · Com Par $.01 | 75,000 | $8.0M | 0.4% | -60.5% | 13F ↗ |
| 35 | FTH Faeth Therapeutics, Inc. | 1.03M | $7.7M | 0.4% | +236% | 13F ↗ |
| 36 | ELVN Enliven Therapeutics, Inc. | 150,000 | $7.6M | 0.4% | New | 13F ↗ |
| 37 | TARS Tarsus Pharmaceuticals, Inc. | 100,000 | $6.3M | 0.3% | -55.6% | 13F ↗ |
| 38 | IBIO iBio, Inc. | 3.57M | $6.2M | 0.3% | New | 13F ↗ |
| 39 | Crinetics Pharmaceuticals In | 125,000 | $4.7M | 0.2% | -50.0% | 13F ↗ |
| 40 | ARQT Arcutis Biotherapeutics, Inc. | 175,000 | $4.6M | 0.2% | -61.1% | 13F ↗ |
| 41 | ARWR Arrowhead Pharmaceuticals, Inc. | 50,000 | $4.1M | 0.2% | -50.0% | 13F ↗ |
| 42 | GPCR Structure Therapeutics Inc. | 75,000 | $4.0M | 0.2% | -57.1% | 13F ↗ |
| 43 | RACC Research Alliance Corporation III | 370,000 | $4.0M | 0.2% | New | 13F ↗ |
| 44 | COGT Cogent Biosciences, Inc. | 100,000 | $3.9M | 0.2% | -50.0% | 13F ↗ |
| 45 | ALT Altimmune, Inc. | 1.25M | $3.8M | 0.2% | New | 13F ↗ |
| 46 | AMLX Amylyx Pharmaceuticals, Inc. | 200,000 | $3.6M | 0.2% | -42.9% | 13F ↗ |
| 47 | ODTX Odyssey Therapeutics, Inc. | 175,000 | $3.3M | 0.2% | New | 13F ↗ |
| 48 | PCVX Vaxcyte, Inc. | 50,000 | $2.9M | 0.1% | -50.0% | 13F ↗ |
| 49 | BOLD Boundless Bio, Inc. | 1.00M | $2.5M | 0.1% | New | 13F ↗ |
| 50 | IRLA IRulya Therapeutics Inc. | 5,498 | $100.0K | <0.1% | New | 13F ↗ |
Changes since Q1 2026
13 new, 4 added to, 28 trimmed, 9 exited, 5 unchanged. By estimated dollars.
New positions (13)
| PBLS Parabilis Medicines, Inc. | 4.62M | New | $126.3M |
| CLYM Climb Bio, Inc. | 2.11M | New | $27.5M |
| SYRE Spyre Therapeutics, Inc. | 225,000 | New | $20.0M |
| DFTX Definium Therapeutics, Inc. | 400,000 | New | $18.8M |
| ASND Ascendis Pharma A/S | 50,000 | New | $13.3M |
| KLRA Kailera Therapeutics, Inc. | 550,000 | New | $12.1M |
| ELVN Enliven Therapeutics, Inc. | 150,000 | New | $7.6M |
| IBIO iBio, Inc. | 3.57M | New | $6.2M |
| RACC Research Alliance Corporation III | 370,000 | New | $4.0M |
| ALT Altimmune, Inc. | 1.25M | New | $3.8M |
Added to (4)
Trimmed (28)
| PRAX Praxis Precision Medicines, Inc. | 640,000 | -27.7% | -$82.2M |
| MBX MBX Biosciences, Inc. | 550,000 | -50.9% | -$31.5M |
| EWTX Edgewise Therapeutics, Inc. | 2.51M | -23.0% | -$30.5M |
| MLTX MoonLake Immunotherapeutics | 3.21M | -28.5% | -$24.8M |
| BBIO BridgeBio Pharma, Inc. | 550,000 | -35.3% | -$22.3M |
| OLMA Olema Oncology, Inc. | 2.15M | -44.9% | -$21.9M |
| DNTH Dianthus Therapeutics, Inc. | 750,000 | -21.1% | -$19.5M |
| ALMS Alumis Inc. | 3.29M | -16.8% | -$18.7M |
| EYPT EyePoint, Inc. | 7.00M | -15.3% | -$18.1M |
| NAMS NewAmsterdam Pharma Company N.V. | 500,000 | -47.4% | -$15.3M |
Exited (9)
| Centessa Pharmaceuticals plc ADR | 1.05M | Exited | -$41.7M |
| MAZE Maze Therapeutics, Inc. | 750,000 | Exited | -$22.4M |
| Ascendis Pharma A/S ADR | 95,000 | Exited | -$21.7M |
| Terns Pharmaceuticals Inc | 300,000 | Exited | -$15.8M |
| ZURA Zura Bio Limited | 1.45M | Exited | -$8.6M |
| AXSM Axsome Therapeutics, Inc. | 50,000 | Exited | -$8.5M |
| GLUE Monte Rosa Therapeutics, Inc. | 400,000 | Exited | -$6.6M |
| RLYB Rallybio Corporation | 400,000 | Exited | -$3.6M |
| CNTX Context Therapeutics Inc. | 529,550 | Exited | -$1.4M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer